Search results for “Narcolepsy” companies
Free sign up to view the full data
Key Players
Order by:
Innovation Intensity
With the analysis among 1,032 patents, we discovered top 102 key players by total patent application. Takeda Pharmaceutical Co., Ltd., Eli Lilly & Co., Ligand UK Research Ltd. are dominant in this area. They take 25.39% of the total patent filing.
Takeda Pharmaceutical Co., Ltd.
Osaka-fu, Japan
Patent: 117
Eli Lilly & Co.
Indiana, United States
Patent: 90
Ligand UK Research Ltd.
United Kingdom
Patent: 55
Shire LLC
Kentucky, United States
Patent: 48
Taisho Pharmaceutical Co., Ltd.
Tokyo-to, Japan
Patent: 41
NTG Nordic Transport Group A/S
Denmark
Patent: 36
F. Hoffmann-La Roche Ltd.
Switzerland
Patent: 36
Smithkline Beecham Plc
United Kingdom
Patent: 34
Concert Pharmaceuticals, Inc.
Massachusetts, United States
Patent: 33
Pfizer Products, Inc.
Connecticut, United States
Patent: 33
Startups & Unicorns
Order by:
Innovation Intensity
With the analysis among 1 patents, we discovered top 1 start-ups by total patent application.
STARTUP
Orexia Therapeutics Ltd.
United Kingdom
Patent: 1
Fast-Growing
Order by:
Innovation in recent 5 years
With the analysis among related 194 patents applied in the last 5 years. We discover 33 most active companies in this area. The fast-growing Takeda Pharmaceutical Co., Ltd., Eli Lilly & Co., Jazz Pharmaceuticals Ireland Ltd. take 51.55% of patent filing during this period.
Takeda Pharmaceutical Co., Ltd.
Osaka-fu, Japan
Patent: 76
Eli Lilly & Co.
Indiana, United States
Patent: 13
Jazz Pharmaceuticals Ireland Ltd.
DUBLIN, Ireland
Patent: 11
Avadel Ireland Ltd.
DUBLIN, Ireland
Patent: 9
Société des Produits Nestlé SA
Vaud, Switzerland
Patent: 6
Axsome Therapeutics, Inc.
New York, United States
Patent: 5
CellionBioMed, Inc.
South Korea
Patent: 5
Intra-Cellular Therapies, Inc.
New York, United States
Patent: 4
Concert Pharmaceuticals, Inc.
Massachusetts, United States
Patent: 4
H. Lundbeck A/S
Hovedstaden, Denmark
Patent: 4
New Entrants
Order by:
Innovation in recent 5 years
With the analysis among related 194 patents in last 5 years, we discover 19 new entrants. Avadel Ireland Ltd., Société des Produits Nestlé SA, Axsome Therapeutics, Inc. are the most active new entrants in this area.
Avadel Ireland Ltd.
DUBLIN, Ireland
Patent: 9
Société des Produits Nestlé SA
Vaud, Switzerland
Patent: 6
Axsome Therapeutics, Inc.
New York, United States
Patent: 5
CellionBioMed, Inc.
South Korea
Patent: 5
Korea Research Institute of Chemical Technology
South Korea
Patent: 4
Alkermes, Inc.
Massachusetts, United States
Patent: 3
Axsome Malta Ltd.
undefined undefined
Patent: 3
MEDIZEN HUMANCARE Co., Ltd.
South Korea
Patent: 2
University of Copenhagen
Hovedstaden, Denmark
Patent: 2
United States of America
United States
Patent: 2
Research Institutions
Order by:
Innovation Intensity
With the analysis among 87 patents, we discovered top 12 universities and scientific research institutions by total patent application. University of Tsukuba, President & Fellows of Harvard College, University of Tokyo are dominant in this area. They take 40.23% of the total patent filing.
University of Tsukuba
Osaka-fu, Japan
Patent: 15
President & Fellows of Harvard College
Massachusetts, United States
Patent: 8
University of Tokyo
Tokyo-to, Japan
Patent: 5
University College London
United Kingdom
Patent: 2
University of Copenhagen
Hovedstaden, Denmark
Patent: 2
Tokai University
Tokyo-to, Japan
Patent: 2
University of Helsinki
Finland
Patent: 2
The Johns Hopkins University
United States
Patent: 1
Vanderbilt University
Tennessee, United States
Patent: 1
Tohoku University
Miyagi-ken, Japan
Patent: 1
Keywords Quick Entry
Popular
Physics
Chemistry
Engineering
Materials science
Computer science
Biology
Medicine
MetalElectrodeVoltageSemiconductorPolymerElectricityCoatingFiberDisplay deviceRaw materialElectric motorUltimate tensile strengthNozzleCarbonBuilding constructionAlkylService lifeElectronOxideOxygenSolventControl unitFlangeControl systemDrugLight sourcePistonDiseaseElectric powerHigh pressure
View more
Page generation time: